The Africa Centres for Illness Management and Prevention (Africa CDC) congratulates the Egyptian Drug Authority (EDA) on its historic milestone of incomes the WHO’s Maturity Stage 3 (ML3) designation for medicines regulation, marking Egypt as the primary African nation to attain this standing for each medicines and vaccine regulation. This exceptional milestone highlights Egypt’s management in advancing regulatory excellence and strengthening well being safety throughout the continent.
H.E. Dr. Jean Kaseya, Director Common of Africa CDC, recommended the Egyptian authorities and the EDA, stating, “Egypt’s accomplishment is a supply of immense satisfaction—not just for the nation however for your complete continent. It marks a big step ahead in advancing the African Union’s Agenda 2063 and selling well being fairness. This achievement underscores the transformative energy of investing in strong regulatory methods, that are important for guaranteeing entry to high quality, protected, and efficient medical merchandise.”
Whereas celebrating this progress, Africa CDC emphasizes that Africa stays the one continent with out a regulatory authority that has achieved WHO Maturity Stage 4 (ML4)—the best normal in regulatory excellence. This hole underscores the pressing want to reinforce Africa’s capability to independently guarantee the security, efficacy, and high quality of high-risk medical merchandise. Closing this hole is important for bolstering the continent’s well being safety and resilience.
Dr. Kaseya reiterated Africa CDC’s dedication to addressing this important hole: “We’re steadfast in our mission to help African nations in attaining ML4 standing. Egypt’s progress achieve ML3 for medicines and vaccines powerfully demonstrates what may be achieved via aligned governance, sources, and dedication. Africa CDC will proceed to work intently with the WHO, AMA (African Medicines Company), African Member States, and different companions to speed up this agenda and make sure that Africa attains ML4-level regulatory methods within the close to future.”
The WHO’s International Benchmarking Instrument evaluates the efficiency of nationwide regulatory methods based mostly on over 250 indicators. With its ML3 designation, Egypt is well-positioned to make additional developments towards ML4, setting a mannequin for different African nations.
Egypt’s pharmaceutical business exemplifies native manufacturing for well being safety, producing over 90% of its medicines domestically and exporting to greater than 100 nations. This achievement showcases the essential position of native manufacturing in constructing resilient and self-reliant well being methods.
Africa CDC reaffirms its dedication to working with AMA and supporting all Member States in strengthening their well being methods and regulatory frameworks. Egypt’s success is a testomony to the ability of collaboration, capacity-building, and adherence to worldwide requirements.
Distributed by APO Group on behalf of Africa Centres for Illness Management and Prevention (Africa CDC).
